ML20149E854
| ML20149E854 | |
| Person / Time | |
|---|---|
| Issue date: | 02/08/1988 |
| From: | Martin T NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION I) |
| To: | Schuman D BLOCK DRUG CO., INC. |
| References | |
| REF-QA-99990001-880208 CAL-88-04, CAL-88-4, EA-88-046, EA-88-46, NUDOCS 8802110304 | |
| Download: ML20149E854 (2) | |
Text
-
~
n 4 i..
FEB 08198g J
r Docket No. 99990001 License No: General Licensee CAL No: 88-04 EA:
88-46 Block Drug Company ATTN: David Schuman, Associate Corporate Counsel 257 Cornelison Avenue-Jersey City, New Jersey 07302 Gentlemen:
Subject:
Confirmatory Action Letter 88-04:
Radioactive Contamination From Static Elimination Devices On February 5,1988, NRC Region I inspectors performed measurements which detected radioactive contamination in your Dayton, New Jersey facility. The contamination apparently originated from one or more static. elimination devices containing polonium-210 that are used in that facility.
As a result of the information obtained by our inspectors, Mr. James H. Joyner of my staff contacted you by telephone on February 8,1988 to discuss the steps which are being taken to protect the safety of employees and to assure that products which are handled at your facility do not present a health and safety hazard to the public.
In addition, the need to perform surveys at your Reed and Charnrick facility in Piscataway, New Jersey, which uses the same static elimination devices in its production lines, was also discussed.
During the telephone call you agreed that the following actions have been or will be taken:
1.
No portion of the Dayton facility will be returned to normal access or operation, including shipment of product, until (a) appropriate radiation surveys are conducted, (b) you conclude from those surveys that there is no radiological hazard to your employees or the public, (c) NRC Region I concurs in your conclusions.
1 2.
You will arrange for urine samples to be provided by your employees who have worked in the areas where contamination has been identified and you will arrange to have the samples analyzed promptly by a laboratory capable of measuring polonium-210 in urine.
3.
The product from the Reed and Charnrick facility in Piscataway, New Jersey will be held from distribution and shipment until your consultant performs a radiological survey at the facility, you provide certification to NRC that no radiological contamination has been identified, and the NRC has concurred in the release of the product.
,p k
bM ONtScg 0FFICIAL RECORD COPY BLOCK DRUG COMPANY - 0001.0.0 g g 99990001 PDR 02/08/88
y Block Drug Company 2'
t If your understanding of the actions to be taken are different than those described above, please contact this office within 24 hours2.777778e-4 days <br />0.00667 hours <br />3.968254e-5 weeks <br />9.132e-6 months <br /> of receipt of this letter.
Thank you for your cooperation.
Sincerely,
'OridnM f a Thomas Thomas T. Martin, Director Division of Radiation Safety and Safeguards cc:
Victor Corts, General Manager 2 Charles Court Dayton, New Jersey 08810 Ron Bernacki, FDA Public Document Room (PDR)
Nuclear Safety Information Center (NSIC)
State of New Jersey bec:
l Region I Docket Room (w/ concurrences) l J. Allan, DRA T. Martin, DRSS J. White, DRSS J. Joyner, DRSS K. Abraham, PA0 J. McGrath, SAO F. Costello, DRSS
R. Cunningham, NMSS J. Goldberg, OGC y M. Tayror, E v:DRSS DRSS
.E L S RI-SS FCostello JWhite Jo r
T rt'i n k 2/ 987 2/f/87 2/P/87 2/f/87 gJ 'a RI:E0 R
RI:RA d
DHolody JA an WTRussell e
2/ /87 2/W/87 2/f/87 0FFICIAL RECORD COPY BLOCK DRUG COMPANY - 0002.0.0 02/08/88 l
l l